A look at Spyre Therapeutics Inc’s (SYRE) recent performance gives investors their first glimpse of hope.

On Friday, Spyre Therapeutics Inc (NASDAQ: SYRE) was -5.00% drop from the session before settling in for the closing price of $22.41. A 52-week range for SYRE has been $20.07 – $47.97.

Healthcare Sector giant saw their annual sales slid by -37.38% over the last five years. When this article was written, the company’s average yearly earnings per share was at 91.35%. With a float of $49.81 million, this company’s outstanding shares have now reached $51.40 million.

The firm has a total of 30 workers. Let’s measure their productivity. In terms of profitability, gross margin is 7.49%, operating margin of -18543.86%, and the pretax margin is -20619.19%.

Spyre Therapeutics Inc (SYRE) Insider Activity

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Spyre Therapeutics Inc stocks. The insider ownership of Spyre Therapeutics Inc is 15.15%, while institutional ownership is 96.03%. The most recent insider transaction that took place on Nov 06 ’24, was worth 246,313. In this transaction Director of this company sold 6,700 shares at a rate of $36.76, taking the stock ownership to the 27,360 shares. Before that another transaction happened on Oct 25 ’24, when Company’s Director sold 300 for $36.43, making the entire transaction worth $10,929. This insider now owns 34,060 shares in total.

Spyre Therapeutics Inc (SYRE) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.79 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 91.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 56.88% during the next five years compared to 23.71% growth over the previous five years of trading.

Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators

You can see what Spyre Therapeutics Inc (SYRE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.32.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 9.21, a number that is poised to hit -0.99 in the next quarter and is forecasted to reach -3.77 in one year’s time.

Technical Analysis of Spyre Therapeutics Inc (SYRE)

Analysing the last 5-days average volume posted by the [Spyre Therapeutics Inc, SYRE], we can find that recorded value of 0.5 million was lower than the volume posted last year of 0.58 million. As of the previous 9 days, the stock’s Stochastic %D was 35.60%. Additionally, its Average True Range was 1.47.

During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 5.20%, which indicates a significant decrease from 22.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.07% in the past 14 days, which was lower than the 59.12% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $23.05, while its 200-day Moving Average is $28.32. Now, the first resistance to watch is $22.68. This is followed by the second major resistance level at $24.07. The third major resistance level sits at $25.28. If the price goes on to break the first support level at $20.08, it is likely to go to the next support level at $18.87. Should the price break the second support level, the third support level stands at $17.48.

Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats

There are 51,431K outstanding shares of the company, which has a market capitalization of 1.25 billion. As of now, sales total 890 K while income totals -338,790 K. Its latest quarter income was 0 K while its last quarter net income were -69,030 K.